| Filed On | Filing |
|---|---|
| 29 Oct 2026 | 10-Q |
| 29 Oct 2026 |
8-K: Results of Operations and Financial Condition
Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial |
| 27 Oct 2026 | SCHEDULE 13G/A |
| 01 Oct 2026 |
Form 4: Mainolfi Nello, Director
Received 30,000 shares by exercise or conversion ($62.4K) · Sold 30,000 shares ($3.41M) |
| 01 Oct 2026 | 144 |
| 08 Sep 2026 | SCHEDULE 13G/A |
| 04 Sep 2026 |
Form 4: Adams Brian, Chief Legal Officer
Sold 6,371 shares ($744K) |
| 04 Sep 2026 | 144 |
| 02 Sep 2026 | 144 |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 13 Aug 2026 | SCHEDULE 13G/A |
| 05 Aug 2026 | 10-Q |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
Enrollment completed in KT-621 (STAT6) BROADEN2 Phase 2b AD trial nearly six months ahead of anticipated timeline, with data expected by year-end 2026 |
| 27 Jul 2026 |
Form 4: Rooney Terence, Chief Medical Officer
Received 38,000 shares as a grant or award · Granted 76,000 Stock Option (Right to Buy) |
| 27 Jul 2026 |
Form 3: Rooney Terence, Chief Medical Officer
No securities owned |
| 27 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Dr. Rooney, former immunology leader at Johnson & Johnson, will lead clinical development strategy across Kymera’s industry-leading oral immunology portfolio |
| 07 Jul 2026 |
Form 4: Mainolfi Nello, Director
Received 50,000 shares by exercise or conversion ($104K) · Sold 50,000 shares ($5.95M) |
| 07 Jul 2026 | 144 |
| 02 Jul 2026 |
Form 4: Jacobs Bruce N., Chief Financial Officer
Received 61,378 shares by exercise or conversion ($327K) · Sold 77,109 shares ($8.86M) |
| 02 Jul 2026 |
Form 4: Goodman Noah, Chief Business Officer
Sold 3,389 shares ($387K) |
Loading...